Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis

About this update from Equillium, Inc.

[{"type":"image","alt":"Equillium, Inc.","displaySize":"","headline":null,"caption":"Equillium, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/dfe9df1c61f4d5fd8962074a5b532270"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3BLz5sobFcYFutDllhRufQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/dfe9df1c61f4d5fd8962074a5b532270","width":300,"height":150},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/3BLz5sobFcYFutDllhRufQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMA--/https://media.zenfs.com/en/globenewswire.com/dfe9df1c61f4d5fd8962074a5b532270","width":300,"height":150}},"lazy":false},{"type":"text","content":"Virtual webinar to be held on Wednesday, May 27 at 11:00 AM ET","length":62,"tagName":"p"},{"type":"text","content":"LA JOLLA, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced it will host a virtual investor event on Wednesday, May 27, 2026, at 11:00 AM ET.","length":286,"tagName":"p"},{"type":"text","content":"The event will be presented by Stephen Connelly Ph.D., Equillium’s Chief Scientific Officer, and include new preclinical data evaluating several clinically relevant AhR modulators and further characterization of the relationship between AhR activation and miR-124 induction in both immune and epithelial cells.","length":310,"tagName":"p"},{"type":"text","content":"AhR is a xenosensor essential for maintaining intestinal barrier function and immune homeostasis and its activation initiates a wide transcriptional cascade, driving expression of multiple downstream genes and regulatory micro‑RNA (miR). Of particular interest is miR-124, where published studies in cell and mouse models demonstrated that miR-124 overexpression decreases AhR expression and promotes inflammation, whereas inhibition of miR-124 reduces inflammation. However, these data conflict with the observed anti-inflammatory effects of obefazimod, a drug known to induce miR-124 that has shown clinical efficacy in the treatment of ulcerative colitis. Despite its biological and therapeutic relevance, the paradoxical relationship between AhR and miR-124 has remained elusive and controversial.","le...

More updates from Equillium, Inc.